Your browser doesn't support javascript.
loading
Development and Implementation of a Standardized Heparin Protocol for Left-Sided Pediatric Electrophysiology Procedures.
Moore, Emily F; Pak, Jennifer; Jefferis-Kirk, Christa; Armatage, Arlene; Kronmal, Richard A; Salerno, Jack C; Files, Matthew D.
Afiliação
  • Moore EF; Division of Cardiology and Cardiac Surgery, Heart Center at Seattle Children's Hospital, 4800 Sand Point way NE Mail Stop RC 2.820, Seattle, WA, 98105, USA. emily.moore@seattlechildrens.org.
  • Pak J; Department of Pharmacy, Seattle Children's Hospital, 4800 Sand Point Way NE, Mail stop BM.5.420, Seattle, WA, 98105, USA.
  • Jefferis-Kirk C; Department of Pharmacy, Seattle Children's Hospital, 4800 Sand Point Way NE, Mail stop BM.5.420, Seattle, WA, 98105, USA.
  • Armatage A; Division of Cardiology and Cardiac Surgery, Heart Center at Seattle Children's Hospital, 4800 Sand Point way NE Mail Stop RC 2.820, Seattle, WA, 98105, USA.
  • Kronmal RA; Department of Biostatistics, Collaborative Health Studies Coordinating Center, University of Washington, Bldg. 29, 6200 NE 74th St., Seattle, WA, 98115, USA.
  • Salerno JC; Division of Pediatric Cardiology, Department of Pediatrics, University of Washington, 1959 NE Pacific St., Health Sciences Bldg., Seattle, WA, 98195, USA.
  • Files MD; Division of Pediatric Cardiology, Department of Pediatrics, University of Washington, 1959 NE Pacific St., Health Sciences Bldg., Seattle, WA, 98195, USA.
Pediatr Cardiol ; 39(5): 941-947, 2018 Jun.
Article em En | MEDLINE | ID: mdl-29500504
ABSTRACT
Heparin is used to decrease the risk of thromboembolic complications during electrophysiology studies (EPS); however, there is wide practice variation and minimal evidence to guide heparin dosing, particularly in pediatric patients. This study retrospectively analyzed heparin dosing and response, measured via activated clotting time (ACT), in patients undergoing EPS and used these data (pre-protocol cohort, n = 40), as well as guidance from available literature to implement a standardized heparin protocol (phase 1, n = 43). We utilized quality improvement methodology to refine this protocol (phase 2, n = 40) to improve therapeutic heparin response. Prior to the protocol, patients achieved therapeutic ACT levels (250-350 s) only 35% of the time which improved to 60% during phase 1 (p < 0.05) and to 73% during phase 2 (p < 0.001 compared to pre-protocol). There were no thromboses or significant adverse events in any group. These results demonstrate the effectiveness of a standardized heparin protocol in achieving effective antithrombotic therapy during left-sided pediatric EPS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tromboembolia / Heparina / Ablação por Cateter / Anticoagulantes Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Pediatr Cardiol Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tromboembolia / Heparina / Ablação por Cateter / Anticoagulantes Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Pediatr Cardiol Ano de publicação: 2018 Tipo de documento: Article